logo
ChiesiGrouptoAcquireKalVistaPharmaceuticals,ExpandingitsGlobalRareDiseasePortfolio
===2026/5/7 17:20:20===
gs and product launches; the Company’s plans for international expansion; expectations regarding market adoption and utilization trends; and the Company’s ability to establish and maintain strategic partnerships.

Further information on potential risk factors that could affect the Company’s business and financial results are detailed in the Company’s filings with the SEC, including in the Company’s transition report on Form 10-KT for the transition period from May 1, 2025 to December 31, 2025, the Company’s quarterly reports on Form 10-Q, current reports on Form 8-K, as well as the Schedule 14D-9 to be filed by the Company and the Schedule TO and related tender offer documents to be filed by Parent and Purchaser. You should not place undue reliance on these statements. All forward-looking statements are based on information currently available to the Company and Parent, and the Company and Parent disclaim any obligation to update the information c
=*=*=*=*=*=
当前为第19/21页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页